EP4011391A4 - Biomarker for accessing efficacy of immune checkpoint inhibitor - Google Patents
Biomarker for accessing efficacy of immune checkpoint inhibitor Download PDFInfo
- Publication number
- EP4011391A4 EP4011391A4 EP20849435.1A EP20849435A EP4011391A4 EP 4011391 A4 EP4011391 A4 EP 4011391A4 EP 20849435 A EP20849435 A EP 20849435A EP 4011391 A4 EP4011391 A4 EP 4011391A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- biomarker
- efficacy
- accessing
- immune checkpoint
- checkpoint inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title 1
- 239000000090 biomarker Substances 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/06—Quantitative determination
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019144011 | 2019-08-05 | ||
JP2019216881 | 2019-11-29 | ||
PCT/JP2020/029882 WO2021025031A1 (en) | 2019-08-05 | 2020-08-04 | Biomarker for accessing efficacy of immune checkpoint inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4011391A1 EP4011391A1 (en) | 2022-06-15 |
EP4011391A4 true EP4011391A4 (en) | 2023-08-16 |
Family
ID=74503032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20849435.1A Pending EP4011391A4 (en) | 2019-08-05 | 2020-08-04 | Biomarker for accessing efficacy of immune checkpoint inhibitor |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220283167A1 (en) |
EP (1) | EP4011391A4 (en) |
JP (1) | JPWO2021025031A1 (en) |
KR (1) | KR20220041099A (en) |
CN (1) | CN114206386A (en) |
AU (1) | AU2020327251A1 (en) |
BR (1) | BR112022002098A2 (en) |
CA (1) | CA3149537A1 (en) |
IL (1) | IL290266A (en) |
MX (1) | MX2022001434A (en) |
TW (1) | TW202120692A (en) |
WO (1) | WO2021025031A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116113435A (en) * | 2020-09-08 | 2023-05-12 | 学校法人埼玉医科大学 | Biomarkers for predicting response to cancer treatment |
KR20220158613A (en) | 2021-05-24 | 2022-12-01 | 영남대학교 산학협력단 | Pharmaceutical composition for immuno-oncology for co-administration containing methionine as an active ingredient |
US20230025464A1 (en) * | 2021-07-09 | 2023-01-26 | Macrogenics, Inc. | Pharmaceutical compositions of a pd-1 antibody and use of the same |
CN117281902A (en) * | 2023-11-23 | 2023-12-26 | 广州誉衡生物科技有限公司 | Application of pharmaceutical composition in preparation of melanoma treatment products |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE555319A (en) | 1956-03-21 | 1900-01-01 | ||
US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
JP4488125B2 (en) | 1999-06-30 | 2010-06-23 | ライオン株式会社 | Hair composition |
CN101213297B (en) | 2005-05-09 | 2013-02-13 | 小野药品工业株式会社 | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
KR101411165B1 (en) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | Human monoclonal antibodies to programmed death ligand 1(pd-l1) |
KR101586617B1 (en) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | Antibodies to human programmed death receptor PD-1 |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
CA2923184A1 (en) | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
JP6405457B2 (en) | 2014-09-11 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Macrocyclic inhibitors of PD-1 / PD-L1 and CD80 (B7-1) / PD-L1 protein / protein interaction |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MD3377488T2 (en) | 2015-11-19 | 2023-02-28 | Incyte Corp | Heterocyclic compounds as immunomodulators |
TW201726623A (en) | 2015-12-17 | 2017-08-01 | 英塞特公司 | Heterocyclic compounds as immunomodulators |
MX2018007774A (en) | 2015-12-22 | 2018-11-09 | Incyte Corp | Heterocyclic compounds as immunomodulators. |
EP3190103A1 (en) | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
AR108396A1 (en) | 2016-05-06 | 2018-08-15 | Incyte Corp | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS |
CN109153670B (en) | 2016-05-23 | 2022-03-15 | 中国医学科学院药物研究所 | Nicotinyl alcohol ether derivative, preparation method thereof, pharmaceutical composition and application |
ES2905980T3 (en) | 2016-05-26 | 2022-04-12 | Incyte Corp | Heterocyclic compounds as immunomodulators |
KR20210018253A (en) * | 2018-05-31 | 2021-02-17 | 오노 야꾸힝 고교 가부시키가이샤 | Biomarkers for determining the effectiveness of immune checkpoint inhibitors |
-
2020
- 2020-08-04 TW TW109126354A patent/TW202120692A/en unknown
- 2020-08-04 CA CA3149537A patent/CA3149537A1/en active Pending
- 2020-08-04 MX MX2022001434A patent/MX2022001434A/en unknown
- 2020-08-04 AU AU2020327251A patent/AU2020327251A1/en active Pending
- 2020-08-04 CN CN202080055632.1A patent/CN114206386A/en active Pending
- 2020-08-04 WO PCT/JP2020/029882 patent/WO2021025031A1/en active Application Filing
- 2020-08-04 JP JP2021537327A patent/JPWO2021025031A1/ja active Pending
- 2020-08-04 EP EP20849435.1A patent/EP4011391A4/en active Pending
- 2020-08-04 US US17/632,423 patent/US20220283167A1/en active Pending
- 2020-08-04 BR BR112022002098A patent/BR112022002098A2/en not_active Application Discontinuation
- 2020-08-04 KR KR1020227003427A patent/KR20220041099A/en unknown
-
2022
- 2022-01-31 IL IL290266A patent/IL290266A/en unknown
Non-Patent Citations (7)
Title |
---|
ADIL I. DAUD ET AL: "Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 126, no. 9, 1 September 2016 (2016-09-01), GB, pages 3447 - 3452, XP055585410, ISSN: 0021-9738, DOI: 10.1172/JCI87324 * |
DAUD ADIL I ET AL: "Supplemental Figures: Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma", JOURNAL OF CLINICAL INVESTIGATION, 1 September 2016 (2016-09-01), XP055882336, Retrieved from the Internet <URL:https://dm5migu4zj3pb.cloudfront.net/manuscripts/87000/87324/JCI87324.sd.pdf> [retrieved on 20220121] * |
RIENEKE VAN DE VEN ET AL: "High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes", ERJ OPEN RESEARCH, vol. 3, no. 2, 1 April 2017 (2017-04-01), pages 1 - 9, XP055496353, DOI: 10.1183/23120541.00110-2016 * |
See also references of WO2021025031A1 * |
SI-PEI WU ET AL: "Stromal PD-L1–Positive Regulatory T cells and PD-1–Positive CD8-Positive T cells Define the Response of Different Subsets of Non–Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy", JOURNAL OF THORACIC ONCOLOGY, vol. 13, no. 4, 18 December 2017 (2017-12-18), US, pages 521 - 532, XP055496261, ISSN: 1556-0864, DOI: 10.1016/j.jtho.2017.11.132 * |
TOGASHI YOSUKE ET AL: "Regulatory T cells in cancer immunosuppression - implications for anticancer therapy", NATURE REVIEWS CLINICAL ONCOLOGY, NATURE, NY, US, vol. 16, no. 6, 31 January 2019 (2019-01-31), pages 356 - 371, XP036789413, ISSN: 1759-4774, [retrieved on 20190131], DOI: 10.1038/S41571-019-0175-7 * |
YOSHIKO TAKEUCHI ET AL: "Roles of regulatory T cells in cancer immunity", INTERNATIONAL IMMUNOLOGY, vol. 28, no. 8, 22 August 2016 (2016-08-22), GB, pages 401 - 409, XP055396222, ISSN: 0953-8178, DOI: 10.1093/intimm/dxw025 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2021025031A1 (en) | 2021-02-11 |
KR20220041099A (en) | 2022-03-31 |
WO2021025031A1 (en) | 2021-02-11 |
US20220283167A1 (en) | 2022-09-08 |
IL290266A (en) | 2022-04-01 |
CA3149537A1 (en) | 2021-02-11 |
BR112022002098A2 (en) | 2022-04-12 |
TW202120692A (en) | 2021-06-01 |
MX2022001434A (en) | 2022-02-22 |
CN114206386A (en) | 2022-03-18 |
EP4011391A1 (en) | 2022-06-15 |
AU2020327251A1 (en) | 2022-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4076418A4 (en) | Sos1 inhibitors | |
EP4011391A4 (en) | Biomarker for accessing efficacy of immune checkpoint inhibitor | |
EP3804758A4 (en) | Biomarker for judging efficacy of immune checkpoint inhibitor | |
EP4069212A4 (en) | Inhibitors of hif-2alpha | |
EP3843714A4 (en) | Cd73 inhibitors | |
EP3801503A4 (en) | Inhibitors of sarm1 | |
EP3906029A4 (en) | Inhibitors of menin-mll interaction | |
EP3787635A4 (en) | Cd73 inhibitors | |
EP3982949A4 (en) | Inhibitors of sarm1 | |
EP4051688A4 (en) | Cd73 inhibitors | |
EP3980011A4 (en) | Inhibitors of sarm1 | |
EP3922247A4 (en) | 15-pgdh inhibitor | |
EP3817736A4 (en) | Pikfyve inhibitors | |
EP4077282A4 (en) | Prmt5 inhibitors | |
EP3999517A4 (en) | Cd73 inhibitors | |
EP3801499A4 (en) | Inhibitors of sarm1 | |
EP3956341A4 (en) | Cd73 inhibitors | |
EP4003986A4 (en) | Inhibitor compounds | |
EP3927700A4 (en) | Kinase inhibitors | |
EP3781574A4 (en) | Macrocyclic spiroethers as mcl-1 inhibitors | |
EP3801500A4 (en) | Inhibitors of sarm1 | |
EP3939588A4 (en) | Uses of phosphodiesterase inhibitors | |
EP4076459A4 (en) | Prmt5 inhibitors | |
EP3854224A4 (en) | Immune checkpoint inhibitor | |
EP3976797A4 (en) | Anti-crispr inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220203 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230714 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/0783 20100101ALI20230710BHEP Ipc: G01N 33/569 20060101ALI20230710BHEP Ipc: G01N 33/574 20060101ALI20230710BHEP Ipc: C12Q 1/06 20060101ALI20230710BHEP Ipc: A61P 43/00 20060101ALI20230710BHEP Ipc: A61P 35/02 20060101ALI20230710BHEP Ipc: A61P 35/00 20060101ALI20230710BHEP Ipc: A61K 45/00 20060101ALI20230710BHEP Ipc: A61K 39/395 20060101AFI20230710BHEP |